Symbols / ONCY $1.15 +2.68% Oncolytics Biotech Inc.
ONCY Chart
About
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Fundamentals
Scroll to Statements| Market Cap | 133.55M | Enterprise Value | 128.91M | Income | -28.76M | Sales | — | Book/sh | 0.00 | Cash/sh | 0.04 |
| Dividend Yield | — | Payout | 0.00% | Employees | 29 | IPO | — | P/E | — | Forward P/E | -4.27 |
| PEG | — | P/S | — | P/B | 1601.89 | P/C | — | EV/EBITDA | -4.50 | EV/Sales | — |
| Quick Ratio | 0.95 | Current Ratio | 1.12 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -0.30 | EPS next Y | -0.27 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-14 | ROA | -170.96% | ROE | — | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 116.13M | Shs Float | 113.67M | Short Float | 5.44% |
| Short Ratio | 8.08 | Short Interest | — | 52W High | 1.51 | 52W Low | 0.33 | Beta | 0.99 | Avg Volume | 1.28M |
| Volume | 732.39K | Target Price | $5.15 | Recom | Buy | Prev Close | $1.12 | Price | $1.15 | Change | 2.68% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-17 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-08-13 | init | Lake Street | — → Buy | $7 |
| 2025-05-21 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-05-16 | down | Jones Trading | Buy → Hold | — |
| 2025-03-10 | main | Maxim Group | Buy → Buy | $3 |
| 2025-03-10 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-03-10 | main | RBC Capital | Outperform → Outperform | $5 |
| 2025-02-03 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-09-19 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-08-21 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-05-14 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-04-04 | init | Raymond James | — → Outperform | $3 |
| 2024-03-08 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-02-14 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-01-19 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-01-04 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2023-11-13 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2023-08-16 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-06-29 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
- Rare anal cancer with few options drives Oncolytics' FDA trial push - Stock Titan Mon, 06 Apr 2026 07
- ONCY Should I Buy - Intellectia AI Fri, 17 Apr 2026 07
- $ONCY stock is down 10% today. Here's what we see in our data. - Quiver Quantitative Fri, 10 Apr 2026 19
- Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance Wed, 03 Dec 2025 08
- Is Oncolytics Biotech (ONCY) Price Reset Creating A Long Term Opportunity? - simplywall.st Fri, 10 Apr 2026 07
- ONCY Stock Rallies On Second Fast Track Designation For Experimental Cancer Drug - Stocktwits Wed, 04 Feb 2026 17
- Oncolytics shifts to Nevada as San Diego becomes new headquarters - Stock Titan Wed, 01 Apr 2026 07
- Assessing Oncolytics Biotech (ONCY) Valuation After FDA Fast Track Designation For Pelareorep - Yahoo Finance Mon, 16 Feb 2026 08
- If You Invested $1,000 in Oncolytics Biotech Inc (ONCY) - Stock Titan Sun, 22 Mar 2026 07
- Oncolytics Biotech (ONCY) Leadership Strengthens As Pelareorep Advances - Yahoo Finance Mon, 12 Jan 2026 08
- Insider Purchase: Chief Executive Officer of $ONCY Buys 29,500 Shares | ONCY Stock News - Quiver Quantitative Fri, 13 Feb 2026 08
- Oncolytics Biotech (NASDAQ: ONCY) sets up $75M ATM facility - Stock Titan Mon, 06 Apr 2026 07
- Why Oncolytics Biotech (ONCY) Is Up 19.7% After FDA Fast Track For KRAS-Mutant Colorectal Cancer - Yahoo Finance Sun, 15 Feb 2026 08
- $ONCY stock is up 20% today. Here's what we see in our data. - Quiver Quantitative Wed, 21 Jan 2026 08
- All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy - Yahoo Finance Wed, 19 Nov 2025 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
28.73
+12.46%
|
25.54
+0.28%
|
25.47
+28.40%
|
19.84
|
| Research And Development |
|
13.31
-13.79%
|
15.44
+15.69%
|
13.35
+17.40%
|
11.37
|
| Selling General And Administration |
|
15.41
+52.60%
|
10.10
-14.55%
|
11.82
+44.51%
|
8.18
|
| General And Administrative Expense |
|
15.41
+52.60%
|
10.10
-14.55%
|
11.82
+44.51%
|
8.18
|
| Salaries And Wages |
|
3.86
+13.33%
|
3.41
+14.60%
|
2.97
+4.07%
|
2.86
|
| Other Gand A |
|
11.55
+72.59%
|
6.69
-24.35%
|
8.85
+66.21%
|
5.32
|
| Other Operating Expenses |
|
—
|
—
|
—
|
—
|
| Total Expenses |
|
28.73
+12.46%
|
25.54
+0.28%
|
25.47
+28.40%
|
19.84
|
| Operating Income |
|
-28.73
-12.46%
|
-25.54
-0.28%
|
-25.47
-28.40%
|
-19.84
|
| Total Operating Income As Reported |
|
-28.73
-12.46%
|
-25.54
|
—
|
—
|
| EBITDA |
|
-28.66
-12.57%
|
-25.45
-1.14%
|
-25.17
-28.74%
|
-19.55
|
| Normalized EBITDA |
|
-28.70
-5.05%
|
-27.32
+5.11%
|
-28.79
-38.69%
|
-20.76
|
| Reconciled Depreciation |
|
0.07
-19.54%
|
0.09
-71.36%
|
0.30
+5.18%
|
0.29
|
| EBIT |
|
-28.73
-12.46%
|
-25.54
-0.28%
|
-25.47
-28.40%
|
-19.84
|
| Total Unusual Items |
|
0.05
-97.48%
|
1.87
-48.48%
|
3.63
+199.15%
|
1.21
|
| Total Unusual Items Excluding Goodwill |
|
0.05
-97.48%
|
1.87
-48.48%
|
3.63
+199.15%
|
1.21
|
| Net Income |
|
-28.76
-26.17%
|
-22.79
-8.96%
|
-20.92
-14.32%
|
-18.30
|
| Pretax Income |
|
-28.68
-26.35%
|
-22.70
-8.89%
|
-20.85
-14.31%
|
-18.24
|
| Net Non Operating Interest Income Expense |
|
0.39
-60.41%
|
0.97
-2.46%
|
1.00
+156.93%
|
0.39
|
| Net Interest Income |
|
0.39
-60.41%
|
0.97
-2.46%
|
1.00
+156.93%
|
0.39
|
| Interest Income Non Operating |
|
0.39
-60.41%
|
0.97
-2.46%
|
1.00
+156.93%
|
0.39
|
| Interest Income |
|
0.39
-60.41%
|
0.97
-2.46%
|
1.00
+156.93%
|
0.39
|
| Other Income Expense |
|
-0.34
-118.25%
|
1.87
-48.48%
|
3.63
+199.15%
|
1.21
|
| Other Non Operating Income Expenses |
|
-0.39
|
—
|
—
|
—
|
| Gain On Sale Of Security |
|
0.05
-97.48%
|
1.87
-48.48%
|
3.63
+199.15%
|
1.21
|
| Tax Provision |
|
0.08
-16.84%
|
0.10
+29.92%
|
0.07
+18.14%
|
0.06
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.01
-97.48%
|
0.39
-48.48%
|
0.76
+199.15%
|
0.25
|
| Net Income Including Noncontrolling Interests |
|
-28.76
-26.17%
|
-22.79
-8.96%
|
-20.92
-14.32%
|
-18.30
|
| Net Income From Continuing Operation Net Minority Interest |
|
-28.76
-26.17%
|
-22.79
-8.96%
|
-20.92
-14.32%
|
-18.30
|
| Net Income From Continuing And Discontinued Operation |
|
-28.76
-26.17%
|
-22.79
-8.96%
|
-20.92
-14.32%
|
-18.30
|
| Net Income Continuous Operations |
|
-28.76
-26.17%
|
-22.79
-8.96%
|
-20.92
-14.32%
|
-18.30
|
| Normalized Income |
|
-28.80
-18.65%
|
-24.27
-2.04%
|
-23.78
-23.51%
|
-19.26
|
| Net Income Common Stockholders |
|
-28.76
-26.17%
|
-22.79
-8.96%
|
-20.92
-14.32%
|
-18.30
|
| Diluted EPS |
|
—
|
-0.29
+7.57%
|
-0.31
+2.45%
|
-0.32
|
| Basic EPS |
|
—
|
-0.29
+7.57%
|
-0.31
+2.45%
|
-0.32
|
| Basic Average Shares |
|
—
|
76.48
+13.10%
|
67.62
+16.53%
|
58.03
|
| Diluted Average Shares |
|
—
|
76.48
+13.10%
|
67.62
+16.53%
|
58.03
|
| Diluted NI Availto Com Stockholders |
|
-28.76
-26.17%
|
-22.79
-8.96%
|
-20.92
-14.32%
|
-18.30
|
| Depreciation Amortization Depletion Income Statement |
|
—
|
0.30
-2.75%
|
0.30
+5.18%
|
0.29
|
| Depreciation And Amortization In Income Statement |
|
—
|
0.30
-2.75%
|
0.30
+5.18%
|
0.29
|
| Depreciation Income Statement |
|
—
|
0.30
-2.75%
|
0.30
+5.18%
|
0.29
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
29.26
|
| Current Assets |
|
28.78
|
| Cash Cash Equivalents And Short Term Investments |
|
26.32
|
| Cash And Cash Equivalents |
|
26.32
|
| Other Short Term Investments |
|
0.00
|
| Receivables |
|
0.01
|
| Other Receivables |
|
0.01
|
| Prepaid Assets |
|
2.45
|
| Hedging Assets Current |
|
0.00
|
| Total Non Current Assets |
|
0.49
|
| Net PPE |
|
0.49
|
| Gross PPE |
|
1.01
|
| Accumulated Depreciation |
|
-0.52
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
0.52
|
| Other Properties |
|
0.05
|
| Leases |
|
0.45
|
| Non Current Prepaid Assets |
|
0.00
|
| Total Liabilities Net Minority Interest |
|
8.49
|
| Current Liabilities |
|
3.19
|
| Payables And Accrued Expenses |
|
2.69
|
| Payables |
|
0.82
|
| Accounts Payable |
|
0.82
|
| Current Accrued Expenses |
|
1.88
|
| Current Debt And Capital Lease Obligation |
|
0.10
|
| Current Capital Lease Obligation |
|
0.10
|
| Other Current Liabilities |
|
0.40
|
| Total Non Current Liabilities Net Minority Interest |
|
5.29
|
| Long Term Debt And Capital Lease Obligation |
|
0.22
|
| Long Term Capital Lease Obligation |
|
0.22
|
| Non Current Deferred Liabilities |
|
5.07
|
| Non Current Deferred Revenue |
|
5.07
|
| Stockholders Equity |
|
20.78
|
| Common Stock Equity |
|
20.78
|
| Capital Stock |
|
324.82
|
| Common Stock |
|
324.82
|
| Share Issued |
|
74.42
|
| Ordinary Shares Number |
|
74.42
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
31.75
|
| Retained Earnings |
|
-336.20
|
| Gains Losses Not Affecting Retained Earnings |
|
0.41
|
| Other Equity Adjustments |
|
0.41
|
| Total Equity Gross Minority Interest |
|
20.78
|
| Total Capitalization |
|
20.78
|
| Working Capital |
|
25.58
|
| Invested Capital |
|
20.78
|
| Total Debt |
|
0.32
|
| Capital Lease Obligations |
|
0.32
|
| Net Tangible Assets |
|
20.78
|
| Tangible Book Value |
|
20.78
|
| Other Equity Interest |
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-20.11
-1.15%
|
-19.88
+7.28%
|
-21.44
-24.62%
|
-17.21
|
| Cash Flow From Continuing Operating Activities |
|
-20.11
-1.15%
|
-19.88
+7.28%
|
-21.44
-24.62%
|
-17.21
|
| Net Income From Continuing Operations |
|
-28.76
-26.17%
|
-22.79
-8.96%
|
-20.92
-14.32%
|
-18.30
|
| Depreciation Amortization Depletion |
|
0.07
-19.54%
|
0.09
-71.36%
|
0.30
+5.18%
|
0.29
|
| Depreciation |
|
0.07
-19.54%
|
0.09
-71.36%
|
0.30
+5.18%
|
0.29
|
| Depreciation And Amortization |
|
0.07
-19.54%
|
0.09
-71.36%
|
0.30
+5.18%
|
0.29
|
| Other Non Cash Items |
|
4.20
+1312.46%
|
0.30
+454.93%
|
0.05
+195.58%
|
-0.06
|
| Stock Based Compensation |
|
3.10
+56.61%
|
1.98
+27.14%
|
1.56
-11.03%
|
1.75
|
| Operating Gains Losses |
|
0.10
+104.95%
|
-1.98
+47.55%
|
-3.77
-218.90%
|
-1.18
|
| Gain Loss On Investment Securities |
|
0.23
+120.10%
|
-1.17
+70.66%
|
-3.98
-27134.53%
|
0.01
|
| Net Foreign Currency Exchange Gain Loss |
|
-0.14
+83.07%
|
-0.81
-480.57%
|
0.21
+117.75%
|
-1.20
|
| Change In Working Capital |
|
1.18
-53.23%
|
2.52
+89.63%
|
1.33
+361.82%
|
0.29
|
| Change In Receivables |
|
2.94
+8485.71%
|
-0.04
-109.18%
|
0.38
+50.05%
|
0.25
|
| Changes In Account Receivables |
|
2.93
+73200.00%
|
0.00
|
—
|
—
|
| Change In Prepaid Assets |
|
0.58
-41.47%
|
0.99
+69.20%
|
0.59
+163.75%
|
-0.92
|
| Change In Payables And Accrued Expense |
|
-0.36
-140.72%
|
0.88
+1603.48%
|
-0.06
-104.80%
|
1.22
|
| Change In Accrued Expense |
|
-0.36
-140.72%
|
0.88
|
—
|
—
|
| Change In Other Working Capital |
|
-1.68
-279.70%
|
0.94
+444.60%
|
0.17
+1472.11%
|
-0.01
|
| Change In Other Current Liabilities |
|
-0.29
-15.81%
|
-0.25
-201.09%
|
0.25
+196.49%
|
-0.26
|
| Investing Cash Flow |
|
-0.01
+96.55%
|
-0.17
-101.14%
|
15.24
+201.40%
|
-15.03
|
| Cash Flow From Continuing Investing Activities |
|
-0.01
+96.55%
|
-0.17
-101.14%
|
15.24
+201.40%
|
-15.03
|
| Net PPE Purchase And Sale |
|
-0.01
+96.55%
|
-0.17
-2785.35%
|
-0.01
+85.12%
|
-0.04
|
| Purchase Of PPE |
|
-0.01
+96.55%
|
-0.17
-2785.35%
|
-0.01
+85.12%
|
-0.04
|
| Capital Expenditure |
|
-0.01
+96.55%
|
-0.17
-2785.35%
|
-0.01
+85.12%
|
-0.04
|
| Net Investment Purchase And Sale |
|
—
|
0.00
-100.00%
|
15.25
+201.71%
|
-14.99
|
| Purchase Of Investment |
|
—
|
0.00
|
0.00
+100.00%
|
-14.99
|
| Sale Of Investment |
|
—
|
0.00
-100.00%
|
15.25
|
0.00
|
| Financing Cash Flow |
|
14.12
+180.83%
|
5.03
-79.15%
|
24.12
+168.19%
|
8.99
|
| Cash Flow From Continuing Financing Activities |
|
14.12
+180.83%
|
5.03
-79.15%
|
24.12
+168.19%
|
8.99
|
| Net Issuance Payments Of Debt |
|
—
|
-0.24
+20.97%
|
-0.31
-9.29%
|
-0.28
|
| Repayment Of Debt |
|
—
|
-0.24
+20.97%
|
-0.31
-9.29%
|
-0.28
|
| Long Term Debt Payments |
|
—
|
-0.24
+20.97%
|
-0.31
-9.29%
|
-0.28
|
| Net Long Term Debt Issuance |
|
—
|
-0.24
+20.97%
|
-0.31
-9.29%
|
-0.28
|
| Net Common Stock Issuance |
|
11.77
+136.24%
|
4.98
-79.10%
|
23.84
+157.27%
|
9.26
|
| Proceeds From Stock Option Exercised |
|
2.38
+4963.83%
|
0.05
-92.02%
|
0.59
+6558.46%
|
0.01
|
| Net Other Financing Charges |
|
-0.03
|
—
|
—
|
—
|
| Changes In Cash |
|
-6.00
+60.09%
|
-15.03
-183.88%
|
17.92
+177.06%
|
-23.25
|
| Effect Of Exchange Rate Changes |
|
0.12
+141.87%
|
-0.29
+26.55%
|
-0.39
-127.29%
|
1.44
|
| Beginning Cash Position |
|
11.08
-58.03%
|
26.40
+200.17%
|
8.79
-71.07%
|
30.40
|
| End Cash Position |
|
5.20
-53.05%
|
11.08
-57.90%
|
26.32
+206.17%
|
8.60
|
| Free Cash Flow |
|
-20.12
-0.30%
|
-20.06
+6.50%
|
-21.45
-24.36%
|
-17.25
|
| Income Tax Paid Supplemental Data |
|
—
|
0.13
+41.73%
|
0.09
+166.89%
|
0.03
|
| Common Stock Issuance |
|
11.77
+136.24%
|
4.98
-79.10%
|
23.84
+157.27%
|
9.26
|
| Issuance Of Capital Stock |
|
11.77
+136.24%
|
4.98
-79.10%
|
23.84
+157.27%
|
9.26
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-06 View
- 8-K2026-04-06 View
- 8-K2026-04-01 View
- 10-K2026-03-30 View
- 8-K2026-03-20 View
- 8-K2026-03-19 View
- 42026-03-13 View
- 42026-03-13 View
- 8-K2026-03-02 View
- 8-K2026-02-24 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 8-K2026-02-04 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|